Display options
Cite
Demasure S, Spriet I, Debruyne PR, et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 2021;1-8doi: 10.1080/0284186X.2021.1989720.
Demasure, S., Spriet, I., Debruyne, P. R., Laenen, A., Wynendaele, W., Baldewijns, M., Dumez, H., Clement, P. M., Wildiers, H., Schöffski, P., Roussel, E., Kinget, L., Albersen, M., & Beuselinck, B. (2021). Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta oncologica (Stockholm, Sweden), 1-8. https://doi.org/10.1080/0284186X.2021.1989720
Demasure, Sofie, et al. "Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study." Acta oncologica (Stockholm, Sweden) vol. (2021): 1-8. doi: https://doi.org/10.1080/0284186X.2021.1989720
Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, Dumez H, Clement PM, Wildiers H, Schöffski P, Roussel E, Kinget L, Albersen M, Beuselinck B. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 2021 Oct 28;1-8. doi: 10.1080/0284186X.2021.1989720. Epub 2021 Oct 28. PMID: 34711121.
Copy Download .nbib Format: NLM
Share it on

Acta Oncol. 2021 Oct 28;1-8. doi: 10.1080/0284186X.2021.1989720. Epub 2021 Oct 28.

Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study.

Acta oncologica (Stockholm, Sweden)

Sofie Demasure, Isabel Spriet, Philip R Debruyne, Annouschka Laenen, Wim Wynendaele, Marcella Baldewijns, Herlinde Dumez, Paul M Clement, Hans Wildiers, Patrick Schöffski, Eduard Roussel, Lisa Kinget, Maarten Albersen, Benoit Beuselinck

Affiliations

  1. Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  2. Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
  3. Department of General Medical Oncology, AZ Groeninge, Kortrijk, School of Life Sciences, Anglia Ruskin University, Cambridge, UK.
  4. Biostatistics and Statistical Bioinformatics Center, Leuven, Belgium.
  5. Department of Medical Oncology, Imelda Ziekenhuis, Bonheiden, Belgium.
  6. Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
  7. Department of Urology, University Hospitals Leuven, Leuven, Belgium.

PMID: 34711121 DOI: 10.1080/0284186X.2021.1989720

Abstract

BACKGROUND: Only a few recent phase III trials with targeted therapies or immune checkpoint inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an overall survival (OS) benefit compared to standard of care. We aimed to study the evolution of OS since the start of systemic therapy from 2000 to 2020.

PATIENTS AND METHODS: Retrospective study on all consecutively treated m-ccRCC patients in three Belgian hospitals starting with systemic therapy. The study outcome was OS since the start of systemic therapy. We used a univariable Cox model for OS with year of the start of therapy as a predictor, and a multivariable analysis including known prognostic factors. Linear and non-linear trends of time were tested.

RESULTS: Five hundred patients were included. In a linear model, the HR for OS depending on the year of the start of therapy was 0.95 (95%CI 0.93-0.97;

CONCLUSION: OS of m-ccRCC patients has been improving significantly over the last 15 years since the introduction of VEGFR-TKIs and ICIs.

Keywords: Renal cell carcinoma; clear-cell; immune checkpoint inhibitors; overall survival; vascular endothelial growth factor receptor tyrosine kinase inhibitors

Publication Types